Judge Rules Unreported Clinical Trial Data Must Be Made Public

The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

TTABOVE: © ISTOCK.COM, FLY PARADE

Afederal judge in the Southern District of New York has ruled that sponsors of clinical trials conducted between 2007 and 2017 are failing to comply with federal law if they do not post their studies’ results to ClinicalTrials.gov, according to STAT. The decision stipulates that reporting requirements outlined in a 2017 final rule to the Food and Drug Administration Amendments Act are applicable to trials completed as far back as 2007, and not just those finished after 2017 as government agencies had mistakenly interpreted the law, reports Endpoints News.

“This decision brings us one step closer to what federal law requires—providing the American public with complete access to clinical trial results on drugs and medical devices approved by the FDA,” the plaintiff’s supervising attorney Christopher Morten tells STAT, adding that the ruling “makes it harder for drug companies, device manufacturers, and other trial sponsors to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Amy Schleunes

    A former intern at The Scientist, Amy studied neurobiology at Cornell University and later earned her MFA in creative writing from the University of Iowa. She is a Los Angeles–based writer, editor, and communications strategist who collaborates on nonfiction books for Harper Collins and Houghton Mifflin Harcourt, and also teaches writing at Johns Hopkins University CTY. Her favorite projects involve sharing the insights of science and medicine.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide